EMA accepts Pfizer's axitinib for review in renal cell carcinoma
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has accepted Pfizer's filing for regulatory review of its anti-angiogenic vascular endothelial growth factor (VEGF) receptor inhibitor, axitinib, for patients with advanced renal cell carcinoma (RCC) after failure of prior systemic treatment.